News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Flu Vaccine Developer Vaxart, Inc. Snags $20 Million


8/7/2013 7:55:33 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Flu-fighting Vaxart Inc. raised $20 million in a Series C round. The San Francisco company, which is developing recombinant vaccines that can be taken by tablet rather than injection, did not list the investors in a Securities and Exchange Commission filing Monday. However, the company listed Richard Markham and Jan Leschly of Care Capital and Michael Finney of Finney Capital as directors. Care Capital participated in Vaxart's $12.5 million Series B financing in 2010, when Finney was Vaxart's acting CEO.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES